SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is the third most frequently diagnosed malignancy worldwide and the second leading cause of cancer-related mortality. Despite immune checkpoint inhibitors improving outcomes for patients with microsatellite instability high (MSI-H) CRC, their effectiveness against microsatellite-stable (MSS) cancers remains restricted. Nivolumab-based combination regimens, which include ipilimumab or binimetinib as components, have shown potential to improve treatment results, but existing studies provide incomplete evidence for their effectiveness.
methodsThe researchers conducted a systematic review and meta-analysis, which included three randomized controlled trials that studied 1085 patients with metastatic CRC. The researchers evaluated two outcomes, which were best overall response (BOR) and treatment-related adverse events (TRAEs). The study utilized random-effects models to manage the clinical and methodological variations that existed between different studies. The researchers conducted subgroup analyses along with sensitivity assessments and publication bias assessments to determine how reliable the findings were.
resultsThe pooled analysis demonstrated no statistically significant difference in overall BOR between nivolumab-based combination therapy and control regimens (RR 1.01; 95% CI 0.79-1.30; p = 0.94) with moderate heterogeneity (I
conclusionIn metastatic CRC patients who receive nivolumab-based combination therapies demonstrate partial tumor responses that increase while their safety profile remains acceptable, but their overall response rates do not improve. The research demonstrates how immunotherapy serves as a standard treatment method for MSI-H disease while emphasizing the need to develop biomarker-driven approaches that enhance treatment selection methods, especially for MSS CRC.
Indexed as
Identifiers
41934582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.